Pathogen Detection and Community Acquired Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02880384|
Recruitment Status : Unknown
Verified June 2018 by Providence Health & Services.
Recruitment status was: Active, not recruiting
First Posted : August 26, 2016
Last Update Posted : June 7, 2018
|Condition or disease||Intervention/treatment||Phase|
|Community Acquired Pneumonia||Other: FilmArray LRTI v.2.0 IUO Panel||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||570 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Projected Influence of Enhanced Pathogen Detection on the Clinical Management of Community-Acquired Pneumonia|
|Actual Study Start Date :||January 2017|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: FilmArray LRTI v.2.0 IUO Panel
Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
Other: FilmArray LRTI v.2.0 IUO Panel
Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
- Pathogen Detection [ Time Frame: 5 Days ]Compare the number of CAP pathogens detected using current diagnostic bundle to the number detected using the FilmArray LRTI v.2.0 IUO Panel.
- Treatment Influence [ Time Frame: 5 Days ]Determine the number of cases in which the FilmArray LRTI v.2.0 IUO Panel could allow for a switch from empiric to specific antimicrobial therapy if the results had been known by the healthcare provider.
- Nasopharyngeal swabs compared to sputum [ Time Frame: 5 Days ]Compare the number of pathogens detected using an approved PCR panel using nasopharyngeal swabs to the number detected using the FilmArray LRTI v.2.0 IUO Panel.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02880384
|United States, Oregon|
|Portland Providence Medical Center|
|Portland, Oregon, United States, 97213|
|Principal Investigator:||David Gilbert, MD||Providence Health & Services|